Warning letter
Village Pharmacy: warning letter of Oct 30, 2017
FDA warning letter 516174 · New Jersey District Office
Key facts
| Reference number | 516174 |
|---|---|
| Company | Village Pharmacy |
| Subject | Compounding Pharmacy/Adulterated Drug Products |
| Issue date | Oct 30, 2017 |
| Posted date | Nov 7, 2017 |
| Issuing office | New Jersey District Office |
| Product type | Drugs |
| CFR sections cited | 201.115, 211.67(a), 211.165(a), 211.166(a) |
| Inspection city | Allentown |
| Inspection ZIP | 08501 |
| Inspection start date | Jun 14, 2016 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- VAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: